NANJING, China, June 15 /PRNewswire-FirstCall/ -- China Biopharmaceuticals Holdings, Inc. ("CBH")(OTC Bulletin Board: CHBP - News), a leading Chinese pharmaceutical company focused on the development, manufacturing and distribution of innovative drugs in China, reported progress towards the completion of the acquisition of all of the shares in RACP Pharmaceutical Holdings Ltd. ("RACP"), and its wholly owned subsidiaries, including Shenyang Enshi Pharmaceutical Co., Ltd. ("Enshi"), from RimAsia Capital Partners L.P. ("RimAsia").
